23andMe considering $749 ‘premium’ service
The corporate, which has raised greater than $780 million in enterprise capital from Alphabet and plenty of different backers, has gone backwards and forwards over time about providing extra in depth genetic testing know-how.
In 2016, 23andMe dismissed its workforce of scientists engaged on next-generation sequencing. At the moment, its CEO Anne Wojcicki informed BuzzFeed Information that the corporate “determined to concentrate on its core enterprise.”
The corporate’s at-home ancestry and well being exams contain a sort of study referred to as “genotyping,” which appears to be like at particular locations within the DNA the place there’s vital information. In distinction, sequencing includes figuring out the sequence of a size of DNA, whether or not it is a brief piece or the entire thing — roughly three billion base pairs.
Sequencing supplies much more doubtlessly helpful information about human well being. But it surely’s dearer, placing it out of attain for a lot of customers, and scientists are nonetheless studying whether or not a lot of the info is related or actionable.
If 23andMe have been to supply a premium service, it might compete with start-ups like Veritas Genetics. Veritas sells its entire genome sequencing check for $1000 and up, relying on whether or not the consumer desires to buy further reviews and evaluation.
Other than its exams, which have now offered to greater than 5 million individuals, 23andMe makes its cash by partnering with pharmaceutical corporations like GSK. It additionally has a analysis and growth division exploring new therapeutic targets for medication.
Correction: An earlier model of this story misstated the present costs for 23andMe’s merchandise. They vary from $99 to $199.
Supply hyperlink – https://www.cnbc.com/2018/09/05/23andme-considering-749-dollar-premium-service.html